- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03648775
Evaluation of the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side
National, Multicentre, Prospective, Observational Study, to Evaluate the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side
HIP50 is a national, multicentre, prospective, observational study, in patients presenting a first low energy per trochanteric hip fracture on one side and treated with Y-STRUT® device implanted on the contralateral proximal femur as percutaneous internal fixation to prevent contralateral hip fracture in case of osteoporosis.
The primary objective of this study is to evaluate the clinical efficacy of the studied medical device by measuring the frequency of patient with a fracture at the implantation site within 1 year after implantation.
A total of 50 patients from France will be enrolled (until December 2020) and followed up to 24 months.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Ambérieu-en-Bugey, Francia, 01500
- Hôpital Privé d'Ambérieu
-
Clamart, Francia, 92140
- Hôpital Antoine Béclère
-
La Tronche, Francia, 38700
- Centre Hospitalier Universitaire Grenoble Alpes
-
Orléans, Francia, 45100
- Centre Hospitalier Régional Orléans
-
Tours, Francia, 37000
- Nouvelle Clinique de Tours Plus St Gatien
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patient of 60 years and older, according to CE indication;
- Patient with information form signed to participate in the study;
- Patients presenting a first low energy hip fracture on one side and having a Y-STRUT® device implanted on the contralateral hip between 0 and 120 days after the treatment of the fracture of the first hip;
Exclusion Criteria:
- Patient who refuse to participate to this study;
- Patient implanted with Y-STRUT® for another indication;
- Patient already enrolled in a clinical study, excluding his participation to HIP50.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frequency of post-operative fracture [Clinical efficacy of the device]
Periodo de tiempo: At 12 months
|
Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
|
At 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frequency of post-operative fracture [Clinical efficacy of the device]
Periodo de tiempo: At 3 and 24 months
|
Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
|
At 3 and 24 months
|
|
Recording of concomitants treatments [safety and feasibility of the device]
Periodo de tiempo: At 3, 12 and 24 months
|
Recording of all concomitants treatments: analgesic for pain, anti-osteoporotic treatment and other treatments.
|
At 3, 12 and 24 months
|
|
Pain [safety and feasibility of the device]
Periodo de tiempo: At 3, 12 and 24 months
|
Self-evaluation of hip pain using VAS (Visual Analogue Scale), going from 0 (no pain) to 10 (maximum).
|
At 3, 12 and 24 months
|
|
Walking conditions [safety and feasibility of the device]
Periodo de tiempo: At 3, 12 and 24 months
|
Assessment of resumption of weight-bearing (yes/no, aid)
|
At 3, 12 and 24 months
|
|
Recording of adverse events and device effects [safety and feasibility of the device]
Periodo de tiempo: At 3, 12 and 24 months
|
Recording of the medical device vigilance: all serious adverse events, all adverse events linked to the device or the operative technique, and any other important event reported.
|
At 3, 12 and 24 months
|
|
Surgical procedure duration [learning curve of the procedure]
Periodo de tiempo: At the end of the inclusion period (24 months from the first included patient)
|
Measuring mean/median intervention duration of each procedure.
Then, all the durations of successive procedures will be compared among all the investigators.
|
At the end of the inclusion period (24 months from the first included patient)
|
|
Hospitalisation duration [learning curve of the procedure]
Periodo de tiempo: At the end of the inclusion period (24 months from the first included patient)]
|
Measuring mean/median hospitalisation duration.
Then, all the durations of successive hospitalisations will be compared among all the investigators.
|
At the end of the inclusion period (24 months from the first included patient)]
|
|
Rate of complications [learning curve of the procedure]
Periodo de tiempo: At the end of the inclusion period (24 months from the first included patient)
|
Assessing types and frequencies of procedures complications (per-op and post-op).
Then, all the rate of complications will be compared among all the investigators.
|
At the end of the inclusion period (24 months from the first included patient)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HIP50
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Osteoporosis
-
Radius Health, Inc.TerminadoOsteoporosis | Riesgo de osteoporosis | Osteoporosis Posmenopáusica | Fractura de osteoporosis | Osteoporosis relacionada con la edad | Osteoporosis localizada en la columna vertebral | Osteoporosis senil | Osteoporosis de vértebras | Osteoporosis VertebralEstados Unidos
-
National Taiwan University HospitalNational Taiwan UniversityAún no reclutandoOsteoporosis | Osteoporosis posmenopáusica | Osteopenia posmenopáusica | Osteoporosis PrimariaTaiwán
-
AmgenTerminadoOsteoporosis posmenopáusica (OPM)Japón
-
Deltanoid PharmaceuticalsTerminadoOsteoporosis posmenopáusica, sitios múltiples
-
Appalachian State UniversityNorth Carolina Agriculture & Technical State UniversityTerminadoOsteoporosis posmenopáusica | Osteoporosis, OsteopeniaEstados Unidos
-
mAbxience Research S.L.TerminadoMujeres posmenopáusicas con osteoporosisPolonia, Serbia, Bulgaria, Georgia, Estonia, Hungría, Letonia, México
-
Radius Health, Inc.TerminadoOsteoporosis | Osteoporosis relacionada con la edad | Osteoporosis relacionada con la edad | Osteoporosis localizada en la columna vertebral | Osteoporosis senil | Osteoporosis de vértebrasEstados Unidos, Polonia, Italia
-
Istanbul Physical Medicine Rehabilitation Training...ReclutamientoOsteoporosis posmenopáusicaTurquía (Türkiye)
-
Bursa City HospitalAún no reclutandoOsteoporosis | Osteoporosis posmenopáusica
-
Riphah International UniversityAún no reclutandoOsteoporosis posmenopáusicaPakistán
Ensayos clínicos sobre Y-STRUT® (Hyprevention, Pessac, Francia)
-
HypreventionTerminadoMetástasis óseas | Fractura patológica de caderaFrancia